Shreyas Joshi, MD, outlines considerations for new agents in BCG-unresponsive NMIBC

In a recent interview with Urology Times®, Shreyas S. Joshi, MD, MPH, outlined some of the key considerations for new agents entering the treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). Namely, he emphasized the importance of efficacy, ease of administration, and cost in choosing between therapies.

Joshi specifically considered these factors in the context of the investigational non-viral gene therapy, detalimogene voraplasmid. Detalimogene is currently under assessment in the phase 2 LEGEND trial (NCT04752722).

Joshi is an associate professor of urology at Emory University in Atlanta, Georgia.